Bolt Biotherapeutics, Inc. (BOLT)
NASDAQ: BOLT · Real-Time Price · USD
0.513
+0.002 (0.33%)
At close: Dec 24, 2024, 12:28 PM
0.490
-0.023 (-4.49%)
After-hours: Dec 24, 2024, 1:44 PM EST
Bolt Biotherapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for BOLT stock have an average target of 1.25, with a low estimate of 1.00 and a high estimate of 1.50. The average target predicts an increase of 143.76% from the current stock price of 0.51.
Analyst Consensus: Hold
* Price targets were last updated on May 15, 2024.
Analyst Ratings
The average analyst rating for BOLT stock from 5 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 5 | 5 | 5 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Nov 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Aug 15, 2024 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $3 → $1 | Buy → Hold | Downgrades | $3 → $1 | +95.01% | May 15, 2024 |
| Jones Trading | Jones Trading | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | May 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | May 15, 2024 |
Financial Forecast
Revenue This Year
8.65M
from 7.88M
Increased by 9.87%
Revenue Next Year
4.64M
from 8.65M
Decreased by -46.43%
EPS This Year
-1.65
from -1.83
EPS Next Year
-1.14
from -1.65
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 9.1M | 9.3M | 12.8M | |||
| Avg | 8.7M | 4.6M | 7.3M | |||
| Low | 8.0M | 980,000 | 294,000 |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 15.1% | 7.4% | 175.3% | |||
| Avg | 9.9% | -46.4% | 57.5% | |||
| Low | 2.0% | -88.7% | -93.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.65 | -0.99 | -0.78 | |||
| Avg | -1.65 | -1.14 | -0.86 | |||
| Low | -1.61 | -1.41 | -0.97 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.